News BeyondSpring Inc.

Equities

BYSI

KYG108301006

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
2.22 ^USD	+4.23%		+5.21%	+146.67%

29/04	North American Morning Briefing : Investors Brace -2-	DJ
22/04	North American Morning Briefing : Stock Futures -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeyondSpring Files 2023 Annual Report on Form 20-F	30/04	AQ
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results	30/04	AQ
North American Morning Briefing : Investors Brace -2-	29/04	DJ
North American Morning Briefing : Stock Futures -2-	22/04	DJ
North American Morning Briefing : Stock Futures -2-	15/04	DJ
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment	25/03	MT
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	25/03	AQ
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	25/03	CI
BeyondSpring Inc. Announces Executive Changes	18/03	CI
Top Premarket Decliners	06/03	MT
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements	26/02	AQ
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	03/02	CI
BeyondSpring Receives Non-Compliance Notice From Nasdaq	11/01	MT
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K	11/01	AQ
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements	19/12	MT
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements	19/12	AQ
Transcript : BeyondSpring Inc. - Special Call	07/11
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors	07/11	AQ
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity	07/11	CI
BEYONDSPRING AND PROFESSOR K. EISENMANN OF THE UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE PRESENT POSTER HIGHLIGHTING PLINABULIN'S ANTI-CANCER EFFICACY IN PRIMARY AND RECURRENT GLIOBLASTOMA PATIENT DERIVED INVASIVE NEUROSPHERE MODELS	01/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BeyondSpring Inc.

Equities

BYSI

KYG108301006

Summary

Filters